(Health-NewsWire.Net, June 23, 2017 ) Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) targeted therapeutics development and features dormant and discontinued projects.
Publisher's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
For more information about this report at http://www.reportsweb.com/programmed-cell-death-1-ligand-1-pd-l1-or-b7-homolog-1-or-cd274-pipeline-review-h2-2016
Report Scope
- The report provides a snapshot of the global therapeutic landscape for Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - The report reviews Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) targeted therapeutics and enlists all their major and minor projects - The report assesses Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) targeted therapeutics
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001492663/sample
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Key Company profiles
Abeome Corporation Alnylam Pharmaceuticals, Inc. AlphaMab Co., Ltd AstraZeneca Plc Aurigene Discovery Technologies Limited Avacta Group Plc BeiGene, Ltd. Bristol-Myers Squibb Company CBT Pharmaceuticals Inc CytomX Therapeutics, Inc. Eli Lilly and Company F. Hoffmann-La Roche Ltd. Genosco ImmunoCellular Therapeutics, Ltd. Immunocore Limited IO Biotech ApS Kadmon Corporation, LLC Kymab Limited MedImmune, LLC Merck KGaA Merus NV Novartis AG PsiOxus Therapeutics Limited Regeneron Pharmaceuticals Inc Shanghai Henlius Biotech Co., Ltd. Sorrento Therapeutics, Inc. Sutro Biopharma, Inc. Theravectys SA Tikcro Technologies, Ltd.
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001492663/discount
List of Tables
Number of Products under Development for, H2 2016 14 Number of Products under Development by Therapy Area, H2 2016 15 Number of Products under Development by Indication, H2 2016 16 Comparative Analysis by Late Stage Development, H2 2016 19 Comparative Analysis by Early Stage Products, H2 2016 20 Number of Products under Development by Companies, H2 2016 21 Number of Products under Development by Companies, H2 2016 (Contd..1) 22 Products under Development by Companies, H2 2016 23 Products under Development by Companies, H2 2016 (Contd..1) 24 Products under Development by Companies, H2 2016 (Contd..2) 25 Products under Development by Companies, H2 2016 (Contd..3) 26 Products under Development by Companies, H2 2016 (Contd..4) 27 Products under Development by Companies, H2 2016 (Contd..5) 28 Products under Development by Companies, H2 2016 (Contd..6) 29 Products under Development by Companies, H2 2016 (Contd..7) 30 Products under Development by Companies, H2 2016 (Contd..8) 31 Products under Development by Companies, H2 2016 (Contd..9) 32 Products under Development by Companies, H2 2016 (Contd..10) 33 Number of Products under Investigation by Universities/Institutes, H2 2016 34 Products under Investigation by Universities/Institutes, H2 2016 35 Assessment by Monotherapy/Combination Products, H2 2016 36 Number of Products by Stage and Mechanism of Action, H2 2016 37 Number of Products by Stage and Route of Administration, H2 2016 39 Number of Products by Stage and Molecule Type, H2 2016 41 Pipeline by Abeome Corporation, H2 2016 42 Pipeline by Alnylam Pharmaceuticals, Inc., H2 2016 43 Pipeline by AlphaMab Co., Ltd, H2 2016 44 Pipeline by AstraZeneca Plc, H2 2016 45 Pipeline by Aurigene Discovery Technologies Limited, H2 2016 46 Pipeline by Avacta Group Plc, H2 2016 47 Pipeline by BeiGene, Ltd., H2 2016 48 Pipeline by Bristol-Myers Squibb Company, H2 2016 49 Pipeline by CBT Pharmaceuticals Inc, H2 2016 50 Pipeline by CytomX Therapeutics, Inc., H2 2016 51 Pipeline by Eli Lilly and Company, H2 2016 52 Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 53 Pipeline by Genosco, H2 2016 55 Pipeline by ImmunoCellular Therapeutics, Ltd., H2 2016 56 Pipeline by Immunocore Limited, H2 2016 57 Pipeline by IO Biotech ApS, H2 2016 58 Pipeline by Kadmon Corporation, LLC, H2 2016 59 Pipeline by Kymab Limited, H2 2016 60 Pipeline by MedImmune, LLC, H2 2016 61 Pipeline by Merck KGaA, H2 2016 63 Pipeline by Merus NV, H2 2016 64 Pipeline by Novartis AG, H2 2016 65 Pipeline by PsiOxus Therapeutics Limited, H2 2016 66 Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 67 Pipeline by Shanghai Henlius Biotech Co., Ltd., H2 2016 68 Pipeline by Sorrento Therapeutics, Inc., H2 2016 69 Pipeline by Sutro Biopharma, Inc., H2 2016 70 Pipeline by Theravectys SA, H2 2016 71 Pipeline by Tikcro Technologies, Ltd., H2 2016 72 Dormant Projects, H2 2016 167 Discontinued Products, H2 2016 168
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001492663/buy/3500
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com
|